Panic disorder: The psychobiology of external treat and introceptive distress

CNS Spectrums

Volumn 13, Issue 1, 2008, Pages 26-30

  Stein, Dan J ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; BEHAVIOR THERAPY; CASE REPORT; COGNITIVE THERAPY; DYSPNEA; ELECTROCARDIOGRAPHY; HEART PALPITATION; HUMAN; LABORATORY TEST; MALE; MENTAL STRESS; PANIC; PATIENT REFERRAL; PHYSICAL DISEASE; PHYSICAL EXAMINATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PSYCHOBIOLOGY; PSYCHOTHERAPY;

EID: 38949179925     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900016126     Document Type: Article

References (75)

1. Beyenburg S, Mitchell AJ, Schmidt D, Elger CE, Reuber M. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav. 2005;7:161-171.
2. Stein DJ. Cognitive-Affective Neuroscience of Mood and Anxiety Disorders. London, England: Martin Dunitz; 2003.
3. Reiman EM, Raichle ME, Robins E, et al. The application of positron emission tomography to the study of panic disorder. Am J Psychiatry. 1986;143:469-477.
4. Vythilingam M, Anderson ER, Goddard A, et al. Temporal lobe volume in panic disorder - a quantitative magnetic resonance imaging study. Psychiatry Res. 2000;99:75-82.
5. Massana G, Serra-Grahulosa JM, Salgado-Pineda R et al. Parahippocampal gray matter density in panic disorder: a voxel-based morphometry study. Am J Psychiatry. 2003;160:566-568.
6. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, et al. Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. Neuroimage. 2003;19:80-90.
7. Bisaga A, Katz JL, Antonini A, et al. Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry. 1998;155:1178-1183.
8. Lee YS, Hwang J, Kim SJ, et al. Decreased blood flow of temporal regions of the brain in subjects with panic disorder. J Psychiatr Res. 2006;40:528-534.
9. Sakai Y, Kumano H, Nishikawa M, et al. Cerebral glucose metabolism associated with a fear network in panic disorder. Neuroreport. 2005;16:927-931.
10. Eren I, Tükel R, Polat A, Karaman R, Unal S. Evaluation of regional cerebral blood flow changes in panic disorder with Tc99m-HMPAO SPECT. Psychiatry Res. 2003;123:135-143.
11. Uchida RR, Del Ben CM, Santos AC, et al. Decreased left temporal lobe volume of panic patients measured by magnetic resonance imaging. Braz J Med Biot Res. 2003;36:925-929.
12. Bystritsky A, Pontillo D, Powers M, Sabb FW, Craske MG, Bookheimer SY. Functional MRI changes during panic anticipation and imagery exposure. Neuroreport. 2001;12:3953-3957.
13. Fontaine R, Breton G, Déry R, Fontaine S, Elie R. Temporal lobe abnormalities in panic disorder: an MRI study. Biol Psychiatry. 1990;27:304-310.
14. Ontiveros A, Fontaine R, Breton G, Elie R, Fontaine S, Déry R. Correlation of severity of panic disorder and neuroanatomical changes on magnetic resonance imaging. J Neuropsychiatry Clin Neurosci. 1989;1:404-408.
15. De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry. 1993;33:505-512.
16. Nordahl TE, Semple WE, Gross M, et al. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology. 1990;3:261-272.
17. Han DH, Renshaw PF, Dager SR, et al. Altered cingulate white matter connectivity in panic disorder patients. J Psychiatr Res. In press.
18. Pillay SS, Rogowska J, Gruber SA, Simpson N, Yurgelun-Todd DA. Recognition of happy facial affect in panic disorder: an IMRI study. J Anxiety Disord. 2007;21:381-393.
19. Yoo HK, Kim MJ, Kim SJ, et al. Putaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study. Eur J Neurosci. 2005;22:2089-2094.
20. Protopopescu X, Pan H, Tuescher O, et al. Increased brainstem volume in panic disorder: a voxel-based morphometric study. Neuroreport. 2006;17:361-363.
21. Sakai Y, Kumano H, Nishikawa M, et al. Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy. Neuroimage. 2006;33:218-226.
22. Prasko J, Horacek J, Zalesky R, et al. The change of regional brain metabolism (18FDG PET) in panic disorder during the treatment with cognitive behavioral therapy or antidepressants. Neuroendocrinol Lett. 2004;25:340-348.
23. Boshuisen ML, Reinders A, Paans AM, den Boer JA. Changes in rCBF of panic disorder patients due to effective treatment with sertraline. Neuroimage. 2001;13:S1030-S2125.
24. Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S. Mirtazapine in the treatment of panic disorder. Arch Gen Psychiatry. 2002;59:661-662.
25. Nordahl TE, Stein MB, Benkelfat C, et al. Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorders. Biol Psychiatry. 1998;44:998-1006.
26. Mobbs D, Petrovic P, Marchant JL, et al. When fear is near: threat imminence elicits prefrontal-periagueductal gray shifts in humans. Science. 2007;317:1079-1083.
27. Neumeister A, Bain E, Nugent AC, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24:589-591.
28. Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res. 2004;132:173-181.
29. Esler M, Lambert E, Alvarenga M, et al. Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. Stress. 2007;10:295-304.
30. Maron E, Shlik J. Serotonin function in panic disorder: important, but why? Neuropsychopharmacology. 2006;31:1-11.
31. Graeff FG. Serotonin, the periaqueductal gray and panic. Neurosci Biobehav Rev. 2004;28:239-259.
32. Ham BJ, Sung Y, Kim N, et al. Decreased GABA levels in anterior cingulate and basal ganglia in medicated subjects with panic disorder: a proton magnetic resonance spectroscopy (1H-MRS) study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:403-411.
33. Goddard AW, Mason GF, Aimai A, et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556-561.
34. Cameron OG, Huang GC, Nichols T, et al. Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in insular cortex of individuals with panic disorder. Arch Gen Psychiatry. 2007;64:793-800.
35. Bremner JD, lnnis RB, White T, et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry. 2000;47:96-106.
36. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715-720.
37. Goddard AW, Charney DS. Toward an integrated neurobiology of panic disorder. J Clin Psychiatry. 1997;58(suppl 2):4-12.
38. Gorman JM, Kent JM, Sullivan GM, Cnplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157:493-505.
39. Papp LA, Klein DF, Gorman JM. Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry. 1993;150:1149-1157.
40. Wilhelm FH, Roth WT. The somatic symptom paradox in DSM-IV anxiety disorders: suggestions for a clinical focus on psychophysiology. Biol Psychol. 2001;57:105-140.
41. Garakani A, Buchsbaum MS, Newmark RE, et al. The effect of doxapram on brain imaging in patients with panic disorder. Eur Neuropsychopharmacol. 2007;17:672-686.
42. Schunck T, Erb G, Mathis A, et al. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage. 2006;31:1197-1208.
43. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry. 2002;52:126-135.
44. Woods SW, Koster K, Krystal JK, et al. Yohimbine alters regional cerebral blood flow in panic disorder. Lancet. 1988;2:678.
45. Stewart RS, Devous MD Sr, Rush AJ, Lane L, Bonte FJ. Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry. 1988;145:442-449.
46. Kent JM, Coplan JD, Mawlawi O, et al. Prediction of panic response to a respiratory stimulant by reduced orbitofrontal cerebral blood flow in panic disorder. Am J Psychiatry. 2005;162:1379-1381.
47. Reiman EM, Raichle ME, Robins E, et al. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry. 1989;46:493-500.
48. Liotti M, Brannan S, Egan G, et al. Brain responses associated with consciousness of breathlessness (air hunger). Proc Natl Acad Sci USA. 2001;98:2035-2040.
49. Corfield DR, Fink GR, Ramsay SC, et al. Activation of limbic structures during C02-stimulated breathing in awake man. Adv Exp Med Biol. 1995;393:331-334.
50. Evans KC, Banzett RB, Adams L, McKay L, Frackowiak RS, Corfield DR. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger, J Neurophysiol. 2002;88:1500-1511.
51. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158:1568-1578.
52. Gratacòs M, Sahún I, Gallego X, Amador-Arjona A, Estivill X, Dierssen M. Candidate genes for panic disorder: insight from human and mouse genetic studies. Genes Brain Behav. 2007;6(suppl 1):2-23.
53. Domschke K, Decken J, O'Donovan MC, Glatt SJ. Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. Am J Med Genet B Neuropsychiatr Genet. 2007;144:667-673.
54. Fyer AJ, Hamilton SR Durner M, et al. A third-pass genome scan in panic disorder: evidence for multiple susceptibility loci. Biol Psychiatry. 2006;60:388-401
55. Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry. 1962;119:432-438.
56. Faravelli C, Webb T, Ambonetti A, Fonnesu F, Sessarego A. Prevalence of traumatic early life events in 31 agoraphobic patients with panic attacks. Am J Psychiatry. 1985;142:1493-1494.
57. Friedman S, Smith L, Fogel D, et al. The incidence and influence of early traumatic life events in patients with panic disorder: a comparison with other psychiatric outpatients. J Anxiety Disord. 2002;16:259-272.
58. Stein MB, Walker JR, Anderson G, et al. Childhood physical and sexual abuse in patients with anxiety disorders and in a community sample. Am J Psychiatry. 1996;153:275-277.
59. Domschke K, Braun M, Ohrmann P, et al. Association of the functional -1019C/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder. Int J Neuropsychopharmacol. 2006;9:349-355.
60. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev. 2001;108:4-32.
61. Panksepp J. Affective consciousness: core emotional feelings in animals and humans. Conscious Cogn. 2005;14:30-80.
62. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry. 1993;50:306-317.
63. Peiffer C, Poline JB, Thivard L, Aubier M, Samson Y. Neural substrates for the perception of acutely induced dyspnea. Am J Respir Crit Care Med. 2001;163:951-957.
64. Banzett RB, Mulnier HE, Murphy K, Rosen SD, Wise RJ, Adams L. Breathlessness in humans activates insular cortex. Neuroreport. 2000;11:2117-2120.
65. Severson CA, Wang W, Pieribone VA, Dohle CI, Richerson GB. Midbrain serotonergic neurons are central pH chemoreceptors. Nat Neurosci. 2003;6:1139-1140.
66. Sinha SS, Goetz RR, Klein DF. Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder. Psychiatry Res. 2007;149:309-314.
67. Isom GE, Elshowihy RM. Interaction of acute and chronic stress with respiration: modification by naloxone. Pharmacol Biochem Behav. 1982;16:599-603.
68. Bandelow B, Brunner E, Broocks A, Beinroth D, Hajak G, Pralle L, Rüther E. The use of the Panic and Agoraphobia Scale in a clinical trial. Psychiatry Res. 1998;77:43-49.
69. Muller JE, Koen L, Stein DJ, Anxiety and medical disorders. Curr Psychiatry Rep. 2005;7:245-251.
70. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567-596.
71. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171-199.
72. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry. 2006;51(suppl 2):9S-91S.
73. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord. 2005;88:27-45.
74. Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry. 2006;188:305-312.
75. Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 2002;63:772-777.